proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

784

Participants

Timeline

Start Date

June 9, 2023

Primary Completion Date

May 14, 2025

Study Completion Date

September 30, 2025

Conditions
Acute Kidney InjuryCardiac SurgerySodium-Glucose Transporter 2 Inhibitor
Interventions
DRUG

Dapagliflozin 10 MG Oral Tablet [Farxiga]

One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).

DRUG

Placebo

One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).

Trial Locations (6)

1090 HM

OLVG, Amsterdam

1105 AZ

Amsterdam UMC, Amsterdam

4818 CK

Amphia Hospital, Breda

7500 KA

Medisch Spectrum Twente, Enschede

2300 RC

Leiden University Medical Center, Leiden

3430 EM

St Antonius Hospital, Nieuwegein

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

lead

Amsterdam UMC

OTHER